2026 Q1 Portfolio Activity
In 2026 Q1, Affinity Asset Advisors, LLC maintained a portfolio of 124 distinct positions. The most significant new addition was STATE STR SPDR S&P 500 ETF T, now representing 6.72% of the total fund value. They heavily accumulated shares in ERASCA INC, increasing the position by 37.2%. Conversely, Affinity Asset Advisors, LLC completely exited their position in SPDR SERIES TRUST.
Position History
hover any row below to update
Loading…
Total Positions
124
Quarter
2026 Q1
Top Holding
SPY (6.7%)
Top 10 Concentration
41.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 124
Affinity Asset Advisors, LLC Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
SPY
PUT
STATE STR SPDR ...
|
PUT Option | 6.72% | — |
#1
Prev: #—
|
8.2 | 200,000 | — |
NEW
|
200,000 | $130,068,000 |
$482.81
+35.8%
|
2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 5.59% | 5.31% |
#2
Prev: #2
|
4.2 | 50,000 | 4.0% |
P
S
|
1,284,926 | $108,152,221 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 5.03% | 3.19% |
#3
4
Prev: #7
|
5.5 | 425,000 | 34.0% |
P
S
|
1,675,000 | $97,401,250 | 2021 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ERAS
ERASCA INC
|
Healthcare | 4.47% | 0.83% |
#4
34
Prev: #38
|
4.8 | 1,450,000 | 37.2% |
P
S
|
5,350,000 | $86,563,000 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
INSM
INSMED INC
|
Healthcare | 4.05% | 4.46% |
#5
2
Prev: #3
|
4.1 | 30,000 | 6.7% |
P
S
|
480,000 | $78,489,600 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ROIV
ROIVANT SCIENCE...
|
Healthcare | 4.01% | 2.10% |
#6
9
Prev: #15
|
4.6 | 1,100,000 | 64.7% |
P
S
|
2,800,000 | $77,560,000 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 3.33% | 2.67% |
#7
3
Prev: #10
|
1.8 | -153,457 | -10.7% |
P
S
|
1,279,134 | $64,519,519 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 2.87% | 0.86% |
#8
28
Prev: #36
|
4.1 | 799,448 | 133.1% |
P
S
|
1,400,000 | $55,608,000 | 2021 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 2.83% | 3.11% |
#9
1
Prev: #8
|
1.6 | -15,000 | -8.1% |
P
S
|
170,000 | $54,772,300 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ANAB
ANAPTYSBIO INC
|
Healthcare | 2.69% | 1.23% |
#10
16
Prev: #26
|
4.1 | 495,308 | 111.4% |
P
S
|
940,000 | $52,132,400 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 2.47% | 1.59% |
#11
8
Prev: #19
|
3.5 | 350,000 | 35.0% |
P
S
|
1,350,000 | $47,736,000 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 2.38% | 2.90% |
#12
3
Prev: #9
|
1.5 | -99,517 | -12.4% |
P
S
|
700,483 | $46,168,835 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 2.33% | 3.88% |
#13
9
Prev: #4
|
1.4 | -100,000 | -19.8% |
P
S
|
405,000 | $45,096,750 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
TEVA
TEVA PHARMACEUT...
|
Healthcare | 2.18% | 2.49% |
#14
1
Prev: #13
|
1.9 | no change | no change |
P
S
|
1,400,000 | $42,168,000 | 2023 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ACLX
ARCELLX INC
|
Healthcare | 2.15% | 1.95% |
#15
1
Prev: #16
|
0.9 | -160,961 | -30.7% |
P
S
|
362,764 | $41,652,562 | 2022 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MRNA
CALL
MODERNA INC
|
CALL Option | 2.10% | — |
#16
Prev: #—
|
4.3 | 800,000 | — |
NEW
|
800,000 | $40,640,000 | 2021 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
NUVL
NUVALENT INC
|
Healthcare | 1.59% | 1.85% |
#17
Prev: #17
|
1.1 | -22,633 | -7.0% |
P
S
|
300,000 | $30,735,000 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 1.53% | 1.27% |
#18
7
Prev: #25
|
1.1 | 12,631 | 2.3% |
P
S
|
562,631 | $29,661,906 | 2022 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 1.52% | 0.27% |
#19
48
Prev: #67
|
3.6 | 235,000 | 204.3% |
P
S
|
350,000 | $29,372,000 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 1.50% | 1.81% |
#20
2
Prev: #18
|
3.6 | 1,850,211 | 57.8% |
P
S
|
5,050,211 | $28,988,211 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 1.49% | 0.71% |
#21
19
Prev: #40
|
3.6 | 400,000 | 114.3% |
P
S
|
750,000 | $28,867,500 | 2022 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MDGL
MADRIGAL PHARMA...
|
Healthcare | 1.49% | 1.03% |
#22
11
Prev: #33
|
3.6 | 23,869 | 76.7% |
P
S
|
55,000 | $28,790,850 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
STRO
SUTRO BIOPHARMA...
|
Healthcare | 1.38% | 0.49% |
#23
26
Prev: #49
|
3.1 | 321,137 | 42.9% |
P
S
|
1,069,519 | $26,641,718 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
FBRX
FORTE BIOSCIENC...
|
Healthcare | 1.35% | 1.54% |
#24
4
Prev: #20
|
1.0 | 22,400 | 2.3% |
P
S
|
1,011,890 | $26,207,951 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 1.27% | 1.39% |
#25
1
Prev: #24
|
0.5 | -302,669 | -37.7% |
P
S
|
499,673 | $24,508,961 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 1.23% | 1.53% |
#26
5
Prev: #21
|
1.0 | -150,000 | -7.0% |
P
S
|
2,000,172 | $23,862,052 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
OVID
OVID THERAPEUTI...
|
Healthcare | 1.22% | 0.66% |
#27
14
Prev: #41
|
3.0 | 3,486,318 | 48.8% |
P
S
|
10,636,318 | $23,612,626 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 1.19% | — |
#28
Prev: #—
|
4.0 | 586,904 | — |
NEW
|
586,904 | $23,006,637 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 1.12% | 0.36% |
#29
28
Prev: #57
|
3.4 | 65,000 | 216.7% |
P
S
|
95,000 | $21,729,350 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MLYS
MINERALYS THERA...
|
Healthcare | 1.05% | 1.51% |
#30
8
Prev: #22
|
0.9 | 20,000 | 2.7% |
P
S
|
750,000 | $20,317,500 | 2023 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 1.03% | 1.09% |
#31
1
Prev: #30
|
2.9 | 289,786 | 27.6% |
P
S
|
1,340,840 | $20,018,741 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
BMY
CALL
BRISTOL-MYERS S...
|
CALL Option | 0.94% | — |
#32
Prev: #—
|
3.9 | 300,000 | — |
NEW
|
300,000 | $18,195,000 | 2022 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 0.94% | 0.86% |
#33
2
Prev: #35
|
1.4 | no change | no change |
P
S
|
172,125 | $18,141,975 | 2021 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 0.82% | 0.54% |
#34
12
Prev: #46
|
2.8 | 150,000 | 42.9% |
P
S
|
500,000 | $15,860,000 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ZURA
ZURA BIO LTD
|
Healthcare | 0.79% | 0.54% |
#35
12
Prev: #47
|
2.8 | 750,632 | 41.4% |
P
S
|
2,564,303 | $15,257,603 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 0.77% | 1.05% |
#36
5
Prev: #31
|
1.3 | no change | no change |
P
S
|
967,620 | $14,998,110 | 2022 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
SVRA
SAVARA INC
|
Healthcare | 0.71% | 0.96% |
#37
3
Prev: #34
|
0.8 | -285,000 | -10.2% |
P
S
|
2,512,153 | $13,716,355 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
OMEROS CORP
|
|
Bond/Debt | 0.68% | 1.10% |
#38
10
Prev: #28
|
1.3 | no change | no change |
P
S
|
6,525,000 | $13,219,226 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
CATX
PERSPECTIVE THE...
|
Healthcare | 0.68% | 0.05% |
#39
49
Prev: #88
|
3.3 | 2,864,582 | 954.9% |
P
S
|
3,164,582 | $13,196,307 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
HELIX ACQUISITI...
|
|
Unknown | 0.66% | — |
#40
Prev: #—
|
3.8 | 1,250,000 | — |
NEW
|
1,250,000 | $12,700,000 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
ARWR
ARROWHEAD PHARM...
|
Healthcare | 0.65% | 0.26% |
#41
27
Prev: #68
|
3.3 | 130,000 | 185.7% |
P
S
|
200,000 | $12,540,000 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
GLTO
DAMORA THERAPEU...
|
Healthcare | 0.60% | — |
#42
Prev: #—
|
3.7 | 450,000 | — |
NEW
|
450,000 | $11,655,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
EPRX
EUPRAXIA PHARMA...
|
Healthcare | 0.59% | 0.13% |
#43
37
Prev: #80
|
3.2 | 1,289,005 | 429.7% |
P
S
|
1,589,005 | $11,504,396 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 0.58% | — |
#44
Prev: #—
|
3.7 | 500,000 | — |
NEW
|
500,000 | $11,240,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 0.58% | 1.39% |
#45
22
Prev: #23
|
0.2 | -170,000 | -53.1% |
P
S
|
150,000 | $11,139,000 | 2020 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CGEM
CULLINAN THERAP...
|
Healthcare | 0.57% | 1.14% |
#46
19
Prev: #27
|
0.2 | -1,150,846 | -59.6% |
P
S
|
781,260 | $11,101,705 | 2021 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
BLTE
BELITE BIO INC
|
Healthcare | 0.54% | 0.18% |
#47
26
Prev: #73
|
3.2 | 45,000 | 225.0% |
P
S
|
65,000 | $10,363,600 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
WVE
WAVE LIFE SCIEN...
|
Healthcare | 0.52% | 2.62% |
#48
37
Prev: #11
|
0.2 | -1,298,273 | -48.1% |
P
S
|
1,401,727 | $10,162,521 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
VERA
VERA THERAPEUTI...
|
Healthcare | 0.52% | 0.72% |
#49
10
Prev: #39
|
1.2 | no change | no change |
P
S
|
250,000 | $10,057,500 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
TYRA
TYRA BIOSCIENCE...
|
Healthcare | 0.51% | — |
#50
Prev: #—
|
3.7 | 257,512 | — |
NEW
|
257,512 | $9,862,710 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 |
Showing 1-50 of 124 holdings